On January 11, 2022, Shanghai Fosun Pharmaceutical (Group) Co., Ltd., a leading innovation-driven international healthcare group in China, and Insilico Medicine, an end-to-end artificial intelligence (AI)-driven drug discovery and development company, announced that they have entered into a collaboration agreement to advance the discovery and development of drugs targeting a number of different targets globally through the use of AI technology. Wilson Sonsini Goodrich & Rosati advised Insilico on the transaction.

The agreement includes an AI-driven drug discovery research and development (R&D) collaboration on four biological targets, as well as the co-development of Insilico’s QPCTL program. Insilico will receive a total upfront payment of $13 million for the R&D collaboration projects and the co-development of the QPCTL program, potential milestone-based payments, and share commercialization profits from the QPCTL program. In addition, Fosun Pharma will make an equity investment in Insilico.

The Wilson Sonsini team representing Insilico in the transaction included IP attorneys Karen Wong, Alex Key, and Chi-Fei Wang, and corporate attorneys Weiheng Chen, Jie Zhu, Xuchao Dong, and Athena Yu.

For more information, please see the companies’ press release.